Hypercell Technologies
Brookhaven, US · Founded 2021 · Delaware corporation · 1 known investors
Hypercell develops rapid on-site diagnostic tests that detect pathogens such as Salmonella and E. coli in the food supply chain, aiming to deliver both speed and lab-grade accuracy. It serves Fortune 100 food processors and food safety teams to help prevent contamination and reduce recalls, primarily in the U.S.
Founders & leadership
BM
Brian McFarlaneChief Commercial Officer
LD
Loic DeblaisChief Science Officer
LD
Loïc DeblaisChief Science Officer
SJ
Sam JactelCo-founder & Senior Advisor
BJ
Bruno JactelFounder
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 1 round · 2021
▶$1.1MraisedSep 2021 · 6 investors · Other TechnologyRule 506(b)
▶$1.1MraisedSep 2021 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Sam JactelExecutive Officer, Director
- Bruno JactelExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.1M
- Minimum investment
- $1
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Hypercell Technologies do?
- Hypercell develops rapid on-site diagnostic tests that detect pathogens such as Salmonella and E. coli in the food supply chain, aiming to deliver both speed and lab-grade accuracy. It serves Fortune 100 food processors and food safety teams to help prevent contamination and reduce recalls, primarily in the U.S.
- Who are Hypercell Technologies's investors?
- Hypercell Technologies's investors include Serra Ventures.
- How much funding has Hypercell Technologies raised?
- Hypercell Technologies has disclosed $1.1M raised across 1 round.
- Where is Hypercell Technologies headquartered?
- Hypercell Technologies is headquartered in Brookhaven, US.